First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

Reck, Martin; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Cheng, Ying; Sakai, Hiroshi; Paz-Ares, Luis; Lu, Shun; John, Thomas; Sun, Xiaowu; Moisei, Aniela; Taylor, Fiona; Lawrance, Rachael; Zhang, Xiaoqing; Sylvester, Judi; Yuan, Yong; Blum, Steven I; Penrod, John R; Carbone, David P

doi:10.1016/j.ejca.2023.01.015

Title

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

Publication Date

2023-01-28

Author(s)

Reck, Martin

Ciuleanu, Tudor-Eliade

Cobo, Manuel

Schenker, Michael

Zurawski, Bogdan

Menezes, Juliana

Richardet, Eduardo

Bennouna, Jaafar

Felip, Enriqueta

Juan-Vidal, Oscar

Alexandru, Aurelia

Cheng, Ying

Sakai, Hiroshi

Paz-Ares, Luis

Lu, Shun

John, Thomas

Sun, Xiaowu

Moisei, Aniela

Taylor, Fiona

Lawrance, Rachael

Zhang, Xiaoqing

Sylvester, Judi

Yuan, Yong

Blum, Steven I

Penrod, John R

Carbone, David P

Subject

CTLA-4 inhibitor

Health-related quality of life

Immune-checkpoint inhibitors

Immunotherapy

Non-small cell lung cancer

Patient-reported outcomes

Programmed death (PD)-1 inhibitor

Symptom burden

Type of document

Journal Article

OrcId

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.1016/j.ejca.2023.01.015

Abstract

In CheckMate 9LA (NCT03215706), first-line nivolumab plus ipilimumab with chemotherapy (2 cycles) significantly improved overall survival versus chemotherapy (4 cycles) in patients with metastatic non-small cell lung cancer and no known sensitising epidermal growth factor receptor/anaplastic lymphoma kinase alterations. We present exploratory patient-reported outcomes (PROs; minimum follow-up, 2 years).

Link

link

Citation

European Journal of Cancer 2023; 183

Jornal Title

European Journal of Cancer

ISSN

1879-0852

Austin Health

Files: